CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −9,000 | $11.99 | $108K | 1,138,064 |
| 2026-10-02 | Dube Michael P VP, Chief Accounting Officer | Sale | −1,864 | $12.43 | $23K | 65,022 |
| 2026-08-21 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −2,785 | $13.00 | $36K | 1,147,064 |
| 2026-08-20 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −19,890 | $12.60 | $251K | 1,149,849 |
| 2026-07-22 | Dulac Edward J III EVP, Chief Financial Officer | Sale | −8,111 | $11.25 | $91K | 148,175 |
| 2026-07-02 | Dulac Edward J III EVP, Chief Financial Officer | Sale 10b5-1 | −4,677 | $18.00 | $84K | 156,286 |
| 2026-07-01 | Dube Michael P VP, Chief Accounting Officer | Sale | −2,641 | $16.78 | $44K | 66,886 |
| 2026-03-02 | BASTA JAMES EVP, General Counsel | Sale | −1,211 | $13.78 | $17K | 156,794 |
| 2026-03-02 | Clark Eliana EVP, Chief Technical Officer | Sale | −607 | $13.78 | $8K | 93,864 |
| 2026-01-05 | LEONARD JOHN M President and CEO | Sale | −34,146 | $9.21 | $314K | 1,013,339 |
| 2026-01-05 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | −8,508 | $9.21 | $78K | 98,533 |
| 2026-01-05 | BASTA JAMES EVP, General Counsel | Sale | −10,397 | $9.21 | $96K | 101,528 |
| 2026-01-05 | Lebwohl David EVP, Chief Medical Officer | Sale | −11,903 | $9.21 | $110K | 121,249 |
| 2026-01-05 | Clark Eliana EVP, Chief Technical Officer | Sale | −9,515 | $9.21 | $88K | 87,118 |
| 2026-01-05 | Dulac Edward J III EVP, Chief Financial Officer | Sale | −6,379 | $9.21 | $59K | 99,683 |
| 2026-01-05 | Dube Michael P VP, Chief Accounting Officer | Sale | −2,989 | $9.21 | $28K | 52,277 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −49,959 | $9.49 | $474K | 1,077,115 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −32,832 | $9.47 | $311K | 1,044,283 |
| 2025-12-11 | LEONARD JOHN M President and CEO | Sale 10b5-1 | −5,355 | $9.59 | $51K | 1,038,928 |
| 2025-10-01 | Schultes Birgit C EVP, Chief Scientific Officer | Sale | −31 | $17.38 | $539 | 105,184 |
Page 1 of 15 · 287 trades